We offer education, events and other related content to give you a better understanding of the Muscle-invasive and Metastatic Bladder Cancer guidelines.
This course compiles the most recent clinical guidelines edited by the EAU in relation to Muscle-invasive and Metastatic Bladder Cancer. Muscle-invasive and Metastatic Bladder Cancer course is divided in 2 learning units. Each Learning Unit consists of multiple choice questions that you can answer by navigating to the corresponding chapter of the Muscle-invasive and Metastatic Bladder Cancer guideline. The questions are offered for self-assessment of your knowledge of the EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer.
Bladder cancer (BC) is the 7th most commonly diagnosed cancer in males. Incidence and mortality rates vary across countries. For about 35% of patients, bladder cancer is either muscle-invasive or metastatic at disease presentation. Non-muscle invasive disease can progress to become muscle-invasive bladder cancer later on in the disease course.
The standard treatment for patients with urothelial muscle invasive bladder cancer (MIBC) is radical cystectomy (RC). However, RC only provides 5-year survival in about 50% of patients. Review the Guidelines on disease management in this sheet.